The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Updates from the ADVANCE study
Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, shares some updates from the ADVANCE study (NCT03290950), which is comparing the combination of daratumumab, carfilzomib, lenalidomide, and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed myeloma. This study is also evaluating measurable residual disease (MRD) negativity as the primary endpoint. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
